Filgrastim and pegfilgrastim are granulocyte colony-stimulating factor products, which have been part of the supportive treatment of cancer patients for years to increase the white blood cell count and absolute neutrophil count with the objective of preventing neutropenic fever in patients at risk because of chemotherapy. Pegfilgrastim is a glycosylated form of filgrastim with a prolonged duration of effect, a reduced renal clearance, and relatively fewer side effects. We present a patient with early breast cancer who developed a rash more than a week after the use of pegfilgrastim. Clinicians must be aware of the possibility of a delayed hypersensitivity reaction as the application of this drug is increasing and an adverse event can result in delay of chemotherapy treatment.
Amgen, Inc. Neupogen (package insert). Thousand Oaks: Amgen, Inc, 2013.
2.
Amgen, Inc. Neulasta (package insert). Thousand Oaks: Amgen, Inc, 2013.
3.
Alvarez-RuizSPeñasPFFernández-HerreraJ. Maculopapular eruption with enlarged macrophages in eight patients receiving G-CSF or GM-CSF. J Eur Acad Dermatol Venereol2004; 18: 310–313.
4.
BrumitMCSheaTCBrecherME. Transfusion medicine illustrated. G-CSF-associated rash in an allogeneic PBPC donor. Transfusion2003; 43: 1343–1343.
5.
FerranMGallardoFSalarA. Granulomatous dermatitis with enlarged histiocytes: A characteristic pattern of granulocyte colony-stimulating factor. Report of two cases and review of the literature. Dermatol2006; 212: 188–193.
6.
BustilloIKaleyKSaifMW. Rash associated with the use of pegylated filgrastim in a patient with advanced pancreatic cancer. Cutan Ocul Toxicol2009; 28: 181–184.
7.
ScottWRSilbersteinLFlatleyR. Cutaneous reaction to pegfilgrastim presenting as severe generalized skin eruption. Br J Dermatol2009; 161: 717–719.
8.
HannaGGEdgarDClarkeJE. A case of prolonged type 1 hypersensitivity reaction to pegfilgrastim. Clin Oncol (R Coll Radiol)2008; 20: 315–316.
9.
DraperBKRobbinsJBStricklinGP. Bullous Sweet’s syndrome in congenital neutropenia: Association with pegfilgrastim. J Am Acad Dermatol2005; 52: 901–905.
10.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), ClarkeMCoatesAS. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet2008; 371: 29–40.
11.
MussHBWoolfSBerryD. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA2005; 293: 1073–1081.
12.
JonesSHomesFAO’ShaughnessyJ. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol2009; 27: 1177–1183.
13.
YounisTRaysonDThompsonK. Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: A systematic review and meta-analysis. Support Care Cancer2012; 20: 2523–2530.
14.
SmithTJKhatcheressianJLymanGH. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol2006; 24: 3187–3205.
15.
KayaAOBuyukberberSCoskunU. Acute erythema and edematous skin reaction and ectropion following docetaxel in a patient with non-small cell lung cancer. Cutan Ocol Toxicol2008; 27: 327–331.
LakinJDCahillRA. Generalized urticaria to cyclophosphamide Type I hypersensitivity to an immunosuppressive agent. J Allergy Clin Immunol1976; 58: 160–171.
18.
PopescuNASheehanMGKouidesPA. Allergic reactions to cyclophosphamide: Delayed clinical expression with positive immediate skin tests to drug metabolites in 5 patients. J Allergy Clin Immunol1996; 97: 26–33.
19.
NaranjoCABustoUSellersEM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 239–245.
20.
The Uppsala Monitoring Centre. The use of WHO-UMC system for standarised causality assessment, http://who-umc.org/Graphics/24734.pdf (accessed 5 June 2014).
